Corcept Therapeutics Inc. Stock
There is an upward development for Corcept Therapeutics Inc. compared to yesterday, with an increase of €0.98 (1.310%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 124 € there is a hugely positive potential of 63.24% for Corcept Therapeutics Inc. compared to the current price of 75.96 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 1.310% | 1.407% | 15.389% | 42.115% | 50.532% | 287.694% | 253.679% |
| Pacira Pharmaceuticals | 2.800% | 4.902% | 7.000% | 15.676% | 15.676% | -44.271% | -54.661% |
| Rockwell Medical Inc. | -2.440% | -5.729% | 2.046% | -58.951% | -60.417% | -16.440% | -92.115% |
| Twist Bioscience Corp | -1.370% | -5.009% | 14.014% | -41.746% | -42.357% | 6.269% | -77.276% |
Comments
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat